24 June 2020 - At the FDA’s request, NeuroRx is submitting an expanded access policy enabling physicians to request RLF-100 for patients who meet the criteria.
NeuroRx, in partnership with Relief Therapeutics today announced that the U.S. FDA awarded fast track designation to NeuroRx for the investigation of RLF-100 (aviptadil) for the treatment of acute lung injury/acute respiratory distress syndrome associated with COVID-19.
RLF-100 is a synthetic form of human vasoactive intestinal peptide which reduces inflammation in the lungs and protects the alveolar type II cells that are believed to be an entry route for the SARS-CoV-2 to invade the lungs.